Heska Corporation (NASDAQ:HSKA) had its price target cut by B. Riley from $96.50 to $93.00 in a research note released on Friday. They currently have a neutral rating on the medical research company’s stock.

A number of other research firms also recently commented on HSKA. Aegis upped their price objective on Heska Corporation from $114.50 to $129.50 and gave the stock a buy rating in a report on Tuesday, August 1st. BidaskClub downgraded Heska Corporation from a buy rating to a hold rating in a report on Sunday, July 16th. Zacks Investment Research upgraded Heska Corporation from a hold rating to a buy rating and set a $109.00 price objective for the company in a report on Friday, August 4th. Benchmark Co. restated a buy rating and set a $120.00 price objective (up from $106.00) on shares of Heska Corporation in a report on Wednesday, August 9th. Finally, Canaccord Genuity started coverage on Heska Corporation in a report on Thursday, October 5th. They set a buy rating and a $115.00 price objective for the company. Five analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus price target of $106.25.

Shares of Heska Corporation (NASDAQ:HSKA) traded up $4.98 on Friday, reaching $86.74. The company’s stock had a trading volume of 145,426 shares, compared to its average volume of 67,052. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.12 and a current ratio of 2.30. The company has a market capitalization of $626.79, a price-to-earnings ratio of 45.41, a P/E/G ratio of 2.53 and a beta of 0.83.

Heska Corporation (NASDAQ:HSKA) last issued its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.40 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.37 by $0.03. The company had revenue of $31.40 million during the quarter, compared to the consensus estimate of $36.10 million. Heska Corporation had a return on equity of 15.35% and a net margin of 10.67%. Heska Corporation’s revenue was down 6.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.45 EPS. analysts expect that Heska Corporation will post 2.04 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece was first reported by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.watchlistnews.com/heska-corporation-hska-given-new-93-00-price-target-at-b-riley/1681539.html.

In related news, CFO John Mcmahon sold 2,608 shares of the company’s stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $101.17, for a total transaction of $263,851.36. Following the completion of the sale, the chief financial officer now directly owns 193 shares of the company’s stock, valued at approximately $19,525.81. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Nancy Wisnewski sold 825 shares of the company’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $102.21, for a total transaction of $84,323.25. Following the sale, the executive vice president now directly owns 38,114 shares of the company’s stock, valued at $3,895,631.94. The disclosure for this sale can be found here. 14.70% of the stock is currently owned by corporate insiders.

Institutional investors have recently made changes to their positions in the stock. Victory Capital Management Inc. purchased a new stake in Heska Corporation during the 1st quarter worth $101,000. Royal Bank of Canada boosted its position in Heska Corporation by 96.9% during the 2nd quarter. Royal Bank of Canada now owns 1,014 shares of the medical research company’s stock worth $103,000 after purchasing an additional 499 shares during the period. State of Alaska Department of Revenue purchased a new stake in Heska Corporation during the 2nd quarter worth $127,000. LS Investment Advisors LLC boosted its position in Heska Corporation by 411.2% during the 2nd quarter. LS Investment Advisors LLC now owns 1,278 shares of the medical research company’s stock worth $130,000 after purchasing an additional 1,028 shares during the period. Finally, PNC Financial Services Group Inc. boosted its position in Heska Corporation by 199.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,484 shares of the medical research company’s stock worth $155,000 after purchasing an additional 988 shares during the period. 80.46% of the stock is owned by hedge funds and other institutional investors.

About Heska Corporation

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Analyst Recommendations for Heska Corporation (NASDAQ:HSKA)

Receive News & Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.